BioNTech was founded by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer, and infectious diseases and other serious diseases.

BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.

BioNTech US is a fully integrated subsidiary with a strong foundation in Europe and a focus on the development of novel neoantigen-targeted T cell therapies, complementing BioNTech’s highly innovative scientific approach and diversified pipeline of transformative cancer medicines.

12 hours ago · BioNTech made its name in the mRNA field after it co-developed a Covid-19 vaccine with Pfizer. mRNA vaccines were heavily utilised during the Covid-19 pandemic, with the 2023 Nobel Prize in ...

BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized manufacturing, either for individualized vaccines or for large …

Nov 4, 2024 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Feb 3, 2025 · About BioNTech Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms with the intent of rapid development of novel biopharmaceuticals.

Aug 16, 2024 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The ...

1 day ago · March 4 (Reuters) - BioNTech (22UAy.DE), opens new tab said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an early-to-mid stage trial of its ...

Apr 3, 2023 · BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers